AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17060222 — intervention group
Group type: COMPARATOR
Intervention: Non-visited group
Number of subjects: 69
Study 15022581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone for five days (12 mg single dose)
Number of subjects: 150
Study 15022581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone less than five days (12 mg single dose)
Number of subjects: 150
Study 15022581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 150
Study 10964582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (Neoral), administered once, dosage not specified
Number of subjects: 14
Study 10964582 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered once, matching CsA
Number of subjects: 14
Study 10964582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (Neoral)
Number of subjects: 14
Study 10964582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8619212 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic tension-free hernia repair
Number of subjects: 120
Study 8619212 — intervention group
Group type: COMPARATOR
Intervention: Open tension-free hernia repair
Number of subjects: 120
Study 1308265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin preoperatively
Number of subjects: 228
Study 1308265 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin + Gentamycin postoperatively
Number of subjects: 228
Study 3872001 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg X kg b.w.‐1 with high-dose fentanyl
Number of subjects: 92
Study 3872001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg X kg b.w.‐1 with high-dose fentanyl
Number of subjects: 92
Study 3872001 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg X kg b.w.‐1 with balanced anaesthesia
Number of subjects: 92
Study 3872001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.05 mg X kg b.w.‐1 + alcuronium 0.125 mg X kg b.w.‐1
Number of subjects: 92
Study 3872001 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg X kg b.w.‐1
Number of subjects: 92
Study 3872001 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium 0.25 mg X kg b.w.‐1
Number of subjects: 92
Study 30628743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomisation (MR)
Number of subjects: 0
Study 30628743 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28840591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated bifurcation BiOSS® stents
Number of subjects: 445
Study 28840591 — intervention group
Group type: COMPARATOR
Intervention: Regular drug-eluting stents (rDES)
Number of subjects: 445
Study 27004662 — intervention group
Group type: EXPERIMENTAL
Intervention: 15m straight line
Number of subjects: 24
Study 27004662 — intervention group
Group type: EXPERIMENTAL
Intervention: FIG8
Number of subjects: 24
Study 27004662 — intervention group
Group type: EXPERIMENTAL
Intervention: 5m trial
Number of subjects: 24
Study 27004662 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 to 30 strides
Number of subjects: 24
Study 25215468 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (arginine, glutamine, HMB) twice daily for 2 weeks
Number of subjects: 9
Study 25215468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22929437 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 (GLP-1)
Number of subjects: 9
Study 20059663 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment (manual therapy, biofeedback, electrical stimulation, dilator insertions, and home exercises) for women with PVD after 8 sessions
Number of subjects: 22
Study 20059663 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without PVD)
Number of subjects: 22
Study 17512098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 23 valent pneumococcal vaccine
Number of subjects: 254
Study 17512098 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 23 valent pneumococcal vaccine
Number of subjects: 254
Study 17512098 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection compared to intramuscular injection
Number of subjects: 254
Study 17512098 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 254
Study 17512098 — intervention group
Group type: COMPARATOR
Intervention: Pre‐vaccination antibody titres >1 microg/ml
Number of subjects: 254
Study 17512098 — intervention group
Group type: COMPARATOR
Intervention: Female gender with subcutaneous injection
Number of subjects: 254
Study 15470483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt intake
Number of subjects: 114
Study 15470483 — intervention group
Group type: COMPARATOR
Intervention: High-salt intake
Number of subjects: 114
Study 15470483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium phase
Number of subjects: 114
Study 15470483 — intervention group
Group type: COMPARATOR
Intervention: High-sodium phase
Number of subjects: 114
Study 11824861 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-24 verapamil 240 mg/day titrated to 360 mg/day
Number of subjects: 406
Study 11824861 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 10 mg/day titrated to 20 mg/day
Number of subjects: 406
Study 11824861 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day titrated to 100 mg/day
Number of subjects: 406
Study 11824861 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 406
Study 11008892 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg b.i.d. oral nilvadipine for 4 weeks
Number of subjects: 12
Study 8618108 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (AMC) 500/125mg tid for 7 days
Number of subjects: 180
Study 8618108 — intervention group
Group type: COMPARATOR
Intervention: Cefetamet pivoxil (CAT) 500mg bid for 7 days
Number of subjects: 180
Study 8618108 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (AMC)
Number of subjects: 180
Study 8618108 — intervention group
Group type: COMPARATOR
Intervention: Cefetamet pivoxil (CAT)
Number of subjects: 180
Study 2127045 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol infusion
Number of subjects: 20
Study 2127045 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 20
Study 6101610 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic substances (initial standard dose)
Number of subjects: 0
Study 6101610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30644628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone
Number of subjects: 22
Study 30644628 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular 0.8 mg naloxone
Number of subjects: 22
Study 30644628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone (two doses)
Number of subjects: 22
Study 30644628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone vs Intramuscular 0.8 mg naloxone
Number of subjects: 22
Study 28507370 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Soft Tissue Mobilization (DSTM)
Number of subjects: 120
Study 28507370 — intervention group
Group type: COMPARATOR
Intervention: Passive Stretching (PS)
Number of subjects: 120
Study 26044854 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 4000 pollen grains/m(3) of Dactylis glomerata pollen
Number of subjects: 0
Study 26044854 — intervention group
Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 0
Study 26044854 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen exposure
Number of subjects: 0
Study 23973868 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Papillary Muscle Infarction (PapMI)
Number of subjects: 738
Study 21243655 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sleep hygiene intervention (infant proximity, noise masking, and dim lighting)
Number of subjects: 240
Study 21243655 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 240
Study 19864452 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (2.5 mg) plus TZD
Number of subjects: 565
Study 19864452 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (5 mg) plus TZD
Number of subjects: 565
Study 19864452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) plus TZD
Number of subjects: 565
Study 17925592 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg daily
Number of subjects: 85
Study 17925592 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 85
Study 17925592 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 85
Study 17925592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 12007948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy
Number of subjects: 0
Study 10728939 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐streptococcal spray treatment
Number of subjects: 342
Study 10728939 — intervention group
Group type: COMPARATOR
Intervention: placebo spray treatment
Number of subjects: 342
Study 7536871 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim treatment for neutrophil recovery
Number of subjects: 35
Study 7536871 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 2027357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and cefotaxime (n = 52)
Number of subjects: 101
Study 2027357 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime plus placebo (n = 49)
Number of subjects: 101
Study 6161557 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethylstarch (LMW‐HES)
Number of subjects: 16
Study 6161557 — intervention group
Group type: COMPARATOR
Intervention: 10% dextran 40 (followed by dextran 60 intraoperatively)
Number of subjects: 16
Study 31025259 — intervention group
Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^9 CFU B. bifidum
Number of subjects: 300
Study 31025259 — intervention group
Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^7 CFU B. bifidum
Number of subjects: 300
Study 31025259 — intervention group
Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^9 CFU B. longum
Number of subjects: 300
Study 31025259 — intervention group
Group type: EXPERIMENTAL
Intervention: In ovo injection of 1 × 10^7 CFU B. longum
Number of subjects: 300
Study 31025259 — intervention group
Group type: COMPARATOR
Intervention: Intact (without injection) control group
Number of subjects: 300
Study 31025259 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-injected (sterile distilled water) control group
Number of subjects: 300
Study 31025259 — intervention group
Group type: EXPERIMENTAL
Intervention: In ovo injection of bifidobacteria strains
Number of subjects: 300
Study 30126448 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline for 8 weeks
Number of subjects: 32
Study 30126448 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 32
Study 30126448 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline for 16 weeks
Number of subjects: 32
Study 28057659 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 at a dose of 108 colony-forming units, orally, twice daily during antibiotic treatment
Number of subjects: 250
Study 28057659 — intervention group
Group type: COMPARATOR
Intervention: Placebo, identically appearing, orally, twice daily during antibiotic treatment
Number of subjects: 250
Study 25527751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with added protein (61.5% of energy from fat; 51.1 ± 7.9 g of protein; 191.9 ± 9.9 kcal added)
Number of subjects: 9
Study 25527751 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal without added protein
Number of subjects: 9
Study 25527751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with added protein
Number of subjects: 9
Study 23207175 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT lens
Number of subjects: 300
Study 23207175 — intervention group
Group type: COMPARATOR
Intervention: Tecsoft Flex lens
Number of subjects: 300
Study 21505892 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxin (L-T4) therapy
Number of subjects: 27
Study 21505892 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 27
Study 18486783 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reposition and internal fixation of displaced or dislocated fractures (Classes II to V)
Number of subjects: 24
Study 18486783 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment of nondisplaced, nondislocated fractures (Classes I and VI)
Number of subjects: 24
Study 16841627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 400 mg/day
Number of subjects: 421
Study 16841627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 421
Study 16841627 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day
Number of subjects: 421
Study 16841627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 12920975 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) set at 5 ml/Kg
Number of subjects: 0
Study 12920975 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) set at 3 ml/Kg
Number of subjects: 0
Study 12920975 — intervention group
Group type: COMPARATOR
Intervention: No Volume Guarantee (VG)
Number of subjects: 0
Study 9929021 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAS
Number of subjects: 42
Study 9929021 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 42
Study 9929021 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary stenting after PTA failure
Number of subjects: 42
Study 7498858 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of verapamil retard (240 mg) and hydrochlorothiazide (12.5 mg)
Number of subjects: 173
Study 7498858 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with verapamil or hydrochlorothiazide
Number of subjects: 173
Study 2258338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (400 mg twice daily, orally)
Number of subjects: 170
Study 2258338 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g twice daily, iv)
Number of subjects: 170
Study 6780235 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxicromil (18 mg twice per day for the first 3 weeks, then 18 mg four times per day for the next 3 weeks)
Number of subjects: 0
Study 6780235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corresponding placebo for a final period of three weeks)
Number of subjects: 0
Study 31904166 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed model
Number of subjects: 118
Study 31904166 — intervention group
Group type: COMPARATOR
Intervention: Half skull
Number of subjects: 118
Study 31274260 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOGNeyes game with eye-tracker for 3 weeks (3 times/week)
Number of subjects: 28
Study 31274260 — intervention group
Group type: COMPARATOR
Intervention: Mouse control
Number of subjects: 28
Study 29191850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg daily)
Number of subjects: 864
Study 29191850 — intervention group
Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 864
Study 26809868 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG4-guided exclusion diet (excluding four food types with the highest antibody titers for 4 weeks)
Number of subjects: 76
Study 26809868 — intervention group
Group type: COMPARATOR
Intervention: Sham group (excluding four foods with the lowest antibody titers)
Number of subjects: 76
Study 24015807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial agency language
Number of subjects: 719
Study 24015807 — intervention group
Group type: COMPARATOR
Intervention: Human agency language
Number of subjects: 719
Study 23244537 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FO) 1 g twice a day for 120 days
Number of subjects: 160
Study 23244537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mineral oil) 1 g twice a day for 120 days
Number of subjects: 160
Study 20645937 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT with depigmented-polymerized mixed tree pollen extract
Number of subjects: 184
Study 20645937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 17932317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (20 mg/kg/d)
Number of subjects: 64
Study 17932317 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 64
Study 15533545 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling (delivered in two 15-min sessions with written material)
Number of subjects: 271
Study 15533545 — intervention group
Group type: COMPARATOR
Intervention: Nutritional education
Number of subjects: 271
Study 12045168 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 630
Study 12045168 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 630
Study 12045168 — intervention group
Group type: COMPARATOR
Intervention: No PFO
Number of subjects: 630
Study 12045168 — intervention group
Group type: COMPARATOR
Intervention: Small PFO
Number of subjects: 630
Study 12045168 — intervention group
Group type: COMPARATOR
Intervention: Large PFO
Number of subjects: 630
Study 12045168 — intervention group
Group type: COMPARATOR
Intervention: Isolated PFO
Number of subjects: 630
Study 12045168 — intervention group
Group type: COMPARATOR
Intervention: PFO with atrial septal aneurysm
Number of subjects: 630
Study 10407789 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn metabolic screening using tandem mass spectrometry
Number of subjects: 0
Study 10407789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian synthesis approach
Number of subjects: 0
Study 7599015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 40
Study 7599015 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 1.5 g
Number of subjects: 40
Study 29570454 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat/second cesarean with ultrasound-guided intervention (Int-G)
Number of subjects: 124
Study 29570454 — intervention group
Group type: COMPARATOR
Intervention: Second cesarean utilizing the usual procedure (CS2-G)
Number of subjects: 124
Study 28851407 — intervention group
Group type: EXPERIMENTAL
Intervention: Second 1000-ml fluid bolus (standard care)
Number of subjects: 0
Study 28851407 — intervention group
Group type: COMPARATOR
Intervention: Maintenance rate fluid only with early commencement of a vasopressor infusion
Number of subjects: 0
Study 28851407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 25103924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) treatment
Number of subjects: 0
Study 25103924 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 23143075 — intervention group
Group type: EXPERIMENTAL
Intervention: Online support group for parents of children with autism spectrum disorders (4-month duration)
Number of subjects: 45
Study 23143075 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study 23143075 — intervention group
Group type: EXPERIMENTAL
Intervention: Online support group for parents of children with autism spectrum disorders
Number of subjects: 45
Study 22021620 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir treatment intensification
Number of subjects: 23
Study 22021620 — intervention group
Group type: COMPARATOR
Intervention: No treatment augmentation (Control)
Number of subjects: 23
Study 18654778 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nailing (EIN)
Number of subjects: 51
Study 18654778 — intervention group
Group type: COMPARATOR
Intervention: Dynamic skeletal traction spica casting (DSTSC)
Number of subjects: 51
Study 18654778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EIN and DSTSC)
Number of subjects: 51
Study 16466830 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy/weight loss foods
Number of subjects: 55
Study 16466830 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy/weight gain foods
Number of subjects: 55
Study 16466830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- to post-weight loss treatment
Number of subjects: 55
Study 16466830 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 55
Study 14970855 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 0
Study 14970855 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0
Study 11733695 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral precues
Number of subjects: 0
Study 11733695 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral precues
Number of subjects: 0
Study 11733695 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized task presentation
Number of subjects: 0
Study 11733695 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked task presentation
Number of subjects: 0
Study 9223393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glimepiride daily for 7 days and 10 mg prior to a hyperglycaemic clamp
Number of subjects: 14
Study 9223393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7895894 — intervention group
Group type: EXPERIMENTAL
Intervention: Alatop test
Number of subjects: 40
Study 7895894 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-prick test
Number of subjects: 40
Study 7895894 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum IgE determination
Number of subjects: 40
Study 3312564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 100
Study 3312564 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole plus amikacin
Number of subjects: 100
Study 3312564 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef
Number of subjects: 100
Study 3312564 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus amikacin
Number of subjects: 100
Study 29266295 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive parenting profile
Number of subjects: 2876